These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 7473076)

  • 1. The relationship between receptor-effector unit heterogeneity and the shape of the concentration-effect profile: pharmacodynamic implications.
    Hoffman A; Goldberg A
    J Pharmacokinet Biopharm; 1994 Dec; 22(6):449-68. PubMed ID: 7473076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interpretation of relative potencies, relative efficacies and apparent affinity constants of agonist drugs estimated from concentration-response curves.
    Mackay D
    J Theor Biol; 1990 Feb; 142(3):415-27. PubMed ID: 2338830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic-pharmacodynamic modelling of the EEG effect of alfentanil in rats: assessment of rapid functional adaptation.
    Cox EH; Kuipers JA; Danhof M
    Br J Pharmacol; 1998 Aug; 124(7):1534-40. PubMed ID: 9723968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between pharmacokinetic half-life and pharmacodynamic half-life in effect-time modeling.
    Keller F; Czock D; Zellner D; Giehl M
    Int J Clin Pharmacol Ther; 1998 Mar; 36(3):168-75. PubMed ID: 9562234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacodynamic analysis of sparse data from concentration- and effect-controlled clinical trials guided by a pilot study. An investigation by simulations.
    Fullerton T; Forrest A; Levy G
    J Pharm Sci; 1996 Jun; 85(6):600-7. PubMed ID: 8773956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacodynamics: strategies for concentration-and effect-controlled clinical trials.
    Ebling WF; Levy G
    Ann Pharmacother; 1996 Jan; 30(1):12-9. PubMed ID: 8773159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New concept of spare receptors and effectors.
    Marunaka Y; Niisato N; Miyazaki H
    J Membr Biol; 2005 Jan; 203(1):31-9. PubMed ID: 15834687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficiency concept in pharmacodynamics.
    Alván G; Paintaud G; Wakelkamp M
    Clin Pharmacokinet; 1999 May; 36(5):375-89. PubMed ID: 10384860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic-pharmacodynamic modeling of the central nervous system effects of heptabarbital using aperiodic EEG analysis.
    Mandema JW; Danhof M
    J Pharmacokinet Biopharm; 1990 Oct; 18(5):459-81. PubMed ID: 1979991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Considerations on pharmacodynamics and pharmacokinetics: can everything be explained by the extent of drug binding to its receptor?
    Castañeda-Hernández G; Granados-Soto V
    Can J Physiol Pharmacol; 2000 Mar; 78(3):199-207. PubMed ID: 10721811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tissue response as a functional discriminator of receptor heterogeneity: effects of mixed receptor populations on Schild regressions.
    Kenakin TP
    Mol Pharmacol; 1992 Apr; 41(4):699-707. PubMed ID: 1569922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigation of a cellular pharmacodynamic model exhibiting sharp response sensitivity and tolerance.
    Siegel RA
    J Pharmacokinet Pharmacodyn; 2007 Feb; 34(1):87-101. PubMed ID: 17160695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and concentration-effect analysis of intravenous RGD891, a platelet GPIIb/IIIa antagonist, using mixed-effects modeling (NONMEM).
    Zannikos PN; Rohatagi S; Jensen BK; DePhillips SL; Rhodes GR
    J Clin Pharmacol; 2000 Oct; 40(10):1129-40. PubMed ID: 11028252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Feasibility of effect-controlled clinical trials of drugs with pharmacodynamic hysteresis using sparse data.
    Ebling WF; Matsumoto Y; Levy G
    Pharm Res; 1996 Dec; 13(12):1804-10. PubMed ID: 8987075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kinetics of combined drug action.
    Koizumi T; Kakemi M; Katayama K
    J Pharmacokinet Biopharm; 1993 Oct; 21(5):593-607. PubMed ID: 8145133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A model for intracellular calcium signaling and the coordinate regulation of hormone biosynthesis, receptors and secretion.
    Leong DA
    Cell Calcium; 1991; 12(2-3):255-68. PubMed ID: 1647877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A two-dimensional mathematical model of non-linear dual-sorption of percutaneous drug absorption.
    George K
    Biomed Eng Online; 2005 Jul; 4():40. PubMed ID: 15992411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single-channel properties of native and cloned rat vanilloid receptors.
    Premkumar LS; Agarwal S; Steffen D
    J Physiol; 2002 Nov; 545(1):107-17. PubMed ID: 12433953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A pharmacodynamic analysis method to determine the relative importance of drug concentration and treatment time on effect.
    Millenbaugh NJ; Wientjes MG; Au JL
    Cancer Chemother Pharmacol; 2000; 45(4):265-72. PubMed ID: 10755313
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.